Singapore-based telemedicine startup Doctor Anywhere raises ~$65.3M Series C led by Asia Partners, bringing its total raised to $140M
Kristie Neo / DealStreetAsia :
Context & Ripple Effects
Doctor Anywhere's Series C is the payoff of a bet placed during the pandemic's first wave: its $27M Series B in April 2020 was earmarked for expansion into Malaysia and the Philippines, and this round — roughly double that raise — is the war chest to execute it. With total funding now at $140M, it sits alongside Indonesia's Halodoc, which closed an $80M Series C led by Astra with Temasek just months earlier, as one of Southeast Asia's best-capitalized teleconsultation platforms.
The regional funding ladder is steep: US peer Doctor on Demand had already reached a $75M Series D and $240M total by mid-2020, while Singapore neighbor Docquity followed with its own $44M Series C a year after this round. Asia Partners leading suggests growth-stage capital now sees Southeast Asian telehealth as an asset class, not an experiment.
First-order effects
- Doctor Anywhere gets the capital to push into Malaysia and the Philippines beyond its home market, converting the expansion promised at Series B into funded operations.
- Asia Partners takes a lead position in one of Southeast Asia's largest telemedicine platforms, anchoring the region's largest telehealth rounds of 2021.
Second-order effects
- Halodoc becomes the direct competitive benchmark: both are Series C-scale platforms racing for the same Southeast Asian consult-and-deliver market, forcing both to spend on country launches and clinician supply rather than profitability.
- Rivals below this funding scale — chat-based models like Curai or professional-network players like Docquity — face pressure to either raise at similar size or differentiate away from generalist teleconsultation.
Third-order effects
- If Series C checks keep flowing at this size, Southeast Asian digital health consolidates around a few multi-country platforms combining consultations with pharmacy delivery, squeezing out single-market or single-service startups.
- Growth investors treating telehealth as a repeatable asset class across emerging Asian markets would make follow-on rounds increasingly winner-take-most on capital, though whether post-pandemic demand sustains those valuations is genuinely unresolved.
The trend: Southeast Asian telemedicine is scaling from national pilots to regionally funded platforms, with Series C rounds like Doctor Anywhere's and Halodoc's marking the shift from pandemic-era experimentation to growth-stage consolidation.